Ignite Creation Date:
2024-05-05 @ 6:37 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00511524
Status:
COMPLETED
Last Update Posted:
2017-08-07
First Post:
2007-08-02
Brief Title:
An Imaging Study to Investigate the Distribution of GW842166X in the Brain
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
An Open Label Positron Emission Tomography PET Study to Investigate Brain Penetration by 11CGW842166 in Healthy Subjects
Status:
COMPLETED
Status Verified Date:
2017-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
GW842166X is being developed for the treatment and management of inflammatory pain GW842166X is a CB2 receptor agonist and the mechanism is not fully understood although it is thought that for the anti-inflammatory action the drug is required to cross inot the brain from the blood This study aims to look at if the drug crosses into the brain once given orally using an imaging technique called positron emission tomography
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None